Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Blinatumomab (Primary) ; Ponatinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Filgrastim; Methotrexate; Methotrexate; Pegfilgrastim; Prednisone; Vincristine
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 11 Jan 2024 Planned End Date changed from 8 Feb 2024 to 28 Feb 2025.
- 11 Jan 2024 Planned primary completion date changed from 8 Feb 2024 to 28 Feb 2025.
- 12 Dec 2023 Results assessing if a reduced intensity regimen of mini-Hyper-CVD (mini-HCVD) with sequential blinatumomab (blina) in combination with ponatinib may further improve outcomes while mitigating the toxicity of intensive chemotherapy and the need for hematopoietic stem cell transplantation (HSCT) were presented at the 65th American Society of Hematology Annual Meeting and Exposition.